These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 8218757

  • 1. Exocrine pancreatic secretion in man following one week of M1-muscarinic receptor blockade.
    Malfertheiner P, Nelson DK, Kemmer TP, Glasbrenner B, Schneider A, Ditschuneit H.
    Aliment Pharmacol Ther; 1993 Aug; 7(4):423-8. PubMed ID: 8218757
    [Abstract] [Full Text] [Related]

  • 2. M1-muscarinic mechanisms regulate interdigestive cycling of motor and secretory activity in human upper gut.
    Nelson DK, Pieramico O, Dahmen G, Dominguez-Muñoz JE, Malfertheiner P, Alder G.
    Dig Dis Sci; 1996 Oct; 41(10):2006-15. PubMed ID: 8888715
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the effects of the M1-receptor antagonist telenzepine and the CCK-receptor antagonist loxiglumide on the pancreatic secretory response to intraduodenal tryptophan in dogs.
    Teyssen S, Niebergall-Roth E, Rausch A, Beglinger C, Riepl RL, Chari S, Singer MV.
    Pancreas; 1996 Nov; 13(4):407-16. PubMed ID: 8899802
    [Abstract] [Full Text] [Related]

  • 4. Influence of the M1-receptor antagonists telenzepine and pirenzepine on pancreatic secretory response to intraduodenal tryptophan in dogs.
    Singer MV, Teyssen S, Küppers U.
    Digestion; 1991 Nov; 48(1):34-42. PubMed ID: 1868967
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of human exocrine pancreatic secretion by the long-acting somatostatin analogue octreotide (SMS 201-995).
    Kemmer TP, Malfertheiner P, Büchler M, Friess H, Meschenmoser L, Ditschuneit H.
    Aliment Pharmacol Ther; 1992 Feb; 6(1):41-50. PubMed ID: 1371938
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of pancreatic secretion under long-term octreotide treatment in humans.
    Friess H, Bordihn K, Ebert M, Malfertheiner P, Kemmer T, Dennler HJ, Büchler MW.
    Digestion; 1994 Feb; 55 Suppl 1():10-5. PubMed ID: 8132133
    [Abstract] [Full Text] [Related]

  • 7. M1 muscarinic mechanisms regulate intestinal-phase gallbladder physiology in humans.
    Nelson DK, Glasbrenner B, Dahmen G, Riepl RL, Malfertheiner P, Adler G.
    Am J Physiol; 1996 Nov; 271(5 Pt 1):G824-30. PubMed ID: 8944697
    [Abstract] [Full Text] [Related]

  • 8. Effect of telenzepine, an M1-selective muscarinic receptor antagonist, in patients with nocturnal asthma.
    Cazzola M, Matera MG, Liccardi G, Sacerdoti G, D'Amato G, Rossi F.
    Pulm Pharmacol; 1994 Apr; 7(2):91-7. PubMed ID: 8081076
    [Abstract] [Full Text] [Related]

  • 9. Influence of high-dose pancreatic enzyme treatment on pancreatic function in healthy volunteers.
    Friess H, Kleeff J, Malfertheiner P, Müller MW, Homuth K, Büchler MW.
    Int J Pancreatol; 1998 Apr; 23(2):115-23. PubMed ID: 9629509
    [Abstract] [Full Text] [Related]

  • 10. Use of caerulein with submaximal doses of secretin as a test of pancreatic function in man.
    Ribet A, Tournut R, Duffaut M, Vaysse N.
    Gut; 1976 Jun; 17(6):431-4. PubMed ID: 955498
    [Abstract] [Full Text] [Related]

  • 11. Comparison of two dose-response techniques to study the pancreatic secretory response to intraduodenal tryptophan in the absence and presence of the M1-receptor antagonist telenzepine.
    Teyssen S, Niebergall E, Chari ST, Singer MV.
    Pancreas; 1995 May; 10(4):368-73. PubMed ID: 7792293
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of cholecystokinin-stimulated pancreaticobiliary output in man by the cholecystokinin receptor antagonist MK-329.
    Cantor P, Olsen O, Gertz BJ, Gjorup I, Worning H.
    Scand J Gastroenterol; 1991 Jun; 26(6):627-37. PubMed ID: 1713709
    [Abstract] [Full Text] [Related]

  • 13. Action of pirenzepine, a new muscarinic antagonist drug, on human pancreatic secretion.
    Nishimura S, Laugier R, Sarles H.
    Scand J Gastroenterol; 1985 Oct; 20(8):990-4. PubMed ID: 3841228
    [Abstract] [Full Text] [Related]

  • 14. Effect of dietary fiber supplementation on the secretory function of the exocrine pancreas in the dog.
    Stock-Damgé C, Bouchet P, Dentinger A, Aprahamian M, Grenier JF.
    Am J Clin Nutr; 1983 Dec; 38(6):843-8. PubMed ID: 6316773
    [Abstract] [Full Text] [Related]

  • 15. Comparison of vasoactive intestinal peptide and secretin in stimulation of pancreatic secretion.
    Konturek SJ, Pucher A, Radecki T.
    J Physiol; 1976 Feb; 255(2):497-509. PubMed ID: 1255530
    [Abstract] [Full Text] [Related]

  • 16. The muscarinic M1-receptor-selective antagonist, telenzepine, had no bronchodilatory effects in COPD patients.
    Ukena D, Wehinger C, Engelstätter R, Steinijans V, Sybrecht GW.
    Eur Respir J; 1993 Mar; 6(3):378-82. PubMed ID: 8472828
    [Abstract] [Full Text] [Related]

  • 17. Effects of telenzepine and L-364,718 on canine pancreatic secretion before and after vagotomy.
    Niebergall-Roth E, Teyssen S, Wetzel D, Hartel M, Beglinger C, Riepl RL, Singer MV.
    Am J Physiol; 1997 Jun; 272(6 Pt 1):G1550-9. PubMed ID: 9227493
    [Abstract] [Full Text] [Related]

  • 18. A small dose of somatostatin inhibits the secretin stimulated secretion of bicarbonate, amylase, and chymotrypsin in man.
    Vatn MH, Schrumpf E, Hanssen KF, Myren J.
    J Endocrinol Invest; 1980 Jun; 3(3):279-82. PubMed ID: 6159391
    [Abstract] [Full Text] [Related]

  • 19. Telenzepine-sensitive muscarinic receptors on rat pancreatic acinar cells.
    Schmid SW, Modlin IM, Tang LH, Stoch A, Rhee S, Nathanson MH, Scheele GA, Gorelick FS.
    Am J Physiol; 1998 Apr; 274(4):G734-41. PubMed ID: 9575856
    [Abstract] [Full Text] [Related]

  • 20. Inhibitory effects of pirenzepine on cholecystokinin and secretin stimulation on exocrine and endocrine rat pancreas.
    Otsuki M, Okabayashi Y, Nakamura T, Fujii M, Oka T, Tani S, Baba S.
    Dig Dis Sci; 1987 Oct; 32(10):1136-44. PubMed ID: 2443324
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.